This generic drug product is bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse® Capsules, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg, of Takeda Pharmaceuticals U.S.A., Inc. Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients aged six years and older, as well as for Moderate to Severe Binge Eating Disorder (BED) in adults.

This approval follows the company’s recent December 2024 USFDA approval for Lisdexamfetamine Dimesylate Chewable Tablets, further expanding Granules’ comprehensive portfolio in the ADHD therapeutic segment and demonstrating the company’s commitment to providing multiple treatment options for patients.

With this latest approval, Granules India Limited now holds a total of 69 ANDA approvals, with 38 secured under the name of Granules India Limited (GIL) and 31 under Granules Pharmaceuticals, Inc. (GPI).

Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited, said “With this latest approval, we are reinforcing our presence in the ADHD treatment space and strengthening our portfolio of complex generics.”

The post Granules Strengthens ADHD Portfolio with FDA Approval for Lisdexamfetamine Dimesylate Capsules appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

Bengaluru, November 27, 2024 – Granules India Limited, a leading global pharmaceutical company, has received validation and approval from the Science Based Targets initiative (SBTi) for its near-term, long-term, and net-zero goals.

These targets, aligned with the 1.5°C pathway, set Granules apart as one of the select Indian pharmaceutical companies with SBTi-validated targets under the initiative’s new guidelines. Granules’ goals are notable for their comprehensive scope and ambition.

Granules India Limited has committed to achieving net-zero greenhouse gas (GHG) emissions across its value chain, including all subsidiaries, by FY2050. In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030, using FY2023 as the baseline, alongside transitioning to 100% renewable electricity. These near-term and long-term targets are aligned with the 1.5°C pathway, emphasizing Granules’ dedication to ambitious climate action and achieving net-zero well before FY2050.

Speaking about this milestone, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules Limited, said, “Sustainability lies at the core of our decision-making and business strategy, as articulated in our purpose statement: healing lives responsibly through pioneering green science. I am proud that Granules has received SBTi validation and approval for our near-term and long-term goals, aligned with the 1.5°C pathway toward net-zero by 2050 or sooner. This milestone strengthens our commitment to accelerate decarbonization, integrate these targets across our operations and supply chain, and drive progress through collaboration and innovation.”

The post Granules’ Net Zero Commitment Validated and Approved by Science Based Targets Initiative appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.